Societal preference values for advanced melanoma health states in the United Kingdom and Australia

BACKGROUND: No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and unintended toxicities associated with treatment. METHODS: Using standard gamble, utilities were elicited from 140 respondents in the United Kingdom and Australia for 13 hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Beusterien, K M, Szabo, S M, Kotapati, S, Mukherjee, J, Hoos, A, Hersey, P, Middleton, M R, Levy, A R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720221/
https://www.ncbi.nlm.nih.gov/pubmed/19603025
http://dx.doi.org/10.1038/sj.bjc.6605187
_version_ 1782170119773880320
author Beusterien, K M
Szabo, S M
Kotapati, S
Mukherjee, J
Hoos, A
Hersey, P
Middleton, M R
Levy, A R
author_facet Beusterien, K M
Szabo, S M
Kotapati, S
Mukherjee, J
Hoos, A
Hersey, P
Middleton, M R
Levy, A R
author_sort Beusterien, K M
collection PubMed
description BACKGROUND: No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and unintended toxicities associated with treatment. METHODS: Using standard gamble, utilities were elicited from 140 respondents in the United Kingdom and Australia for 13 health states. RESULTS: Preferences decreased with reduced treatment responsiveness and with increasing toxicity. CONCLUSIONS: These general population utilities can be incorporated into treatment-specific cost-effectiveness evaluations.
format Text
id pubmed-2720221
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27202212010-08-04 Societal preference values for advanced melanoma health states in the United Kingdom and Australia Beusterien, K M Szabo, S M Kotapati, S Mukherjee, J Hoos, A Hersey, P Middleton, M R Levy, A R Br J Cancer Short Communication BACKGROUND: No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and unintended toxicities associated with treatment. METHODS: Using standard gamble, utilities were elicited from 140 respondents in the United Kingdom and Australia for 13 health states. RESULTS: Preferences decreased with reduced treatment responsiveness and with increasing toxicity. CONCLUSIONS: These general population utilities can be incorporated into treatment-specific cost-effectiveness evaluations. Nature Publishing Group 2009-08-04 2009-07-14 /pmc/articles/PMC2720221/ /pubmed/19603025 http://dx.doi.org/10.1038/sj.bjc.6605187 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Beusterien, K M
Szabo, S M
Kotapati, S
Mukherjee, J
Hoos, A
Hersey, P
Middleton, M R
Levy, A R
Societal preference values for advanced melanoma health states in the United Kingdom and Australia
title Societal preference values for advanced melanoma health states in the United Kingdom and Australia
title_full Societal preference values for advanced melanoma health states in the United Kingdom and Australia
title_fullStr Societal preference values for advanced melanoma health states in the United Kingdom and Australia
title_full_unstemmed Societal preference values for advanced melanoma health states in the United Kingdom and Australia
title_short Societal preference values for advanced melanoma health states in the United Kingdom and Australia
title_sort societal preference values for advanced melanoma health states in the united kingdom and australia
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720221/
https://www.ncbi.nlm.nih.gov/pubmed/19603025
http://dx.doi.org/10.1038/sj.bjc.6605187
work_keys_str_mv AT beusterienkm societalpreferencevaluesforadvancedmelanomahealthstatesintheunitedkingdomandaustralia
AT szabosm societalpreferencevaluesforadvancedmelanomahealthstatesintheunitedkingdomandaustralia
AT kotapatis societalpreferencevaluesforadvancedmelanomahealthstatesintheunitedkingdomandaustralia
AT mukherjeej societalpreferencevaluesforadvancedmelanomahealthstatesintheunitedkingdomandaustralia
AT hoosa societalpreferencevaluesforadvancedmelanomahealthstatesintheunitedkingdomandaustralia
AT herseyp societalpreferencevaluesforadvancedmelanomahealthstatesintheunitedkingdomandaustralia
AT middletonmr societalpreferencevaluesforadvancedmelanomahealthstatesintheunitedkingdomandaustralia
AT levyar societalpreferencevaluesforadvancedmelanomahealthstatesintheunitedkingdomandaustralia

Ejemplares similares